UNITED STATES BANKRUPTCY COURT

DISTRICT OF Delaware

In re: Insys Therapeutics, Inc., § Case No. 19-11292

Debtor(s) §

☐ Jointly Administered

Post-confirmation Report

Chapter 11

Quarter Ending Date: 03/31/2026

Petition Date: 06/10/2019

Plan Confirmed Date: 01/16/2020

Plan Effective Date: 02/18/2020

This Post-confirmation Report relates to: ○ Reorganized Debtor

◉ Other Authorized Party or Entity: Insys Liquidation Trust
Name of Authorized Party or Entity

/s/ Ligee Gu
Signature of Responsible Party

Ligee Gu
Printed Name of Responsible Party

04/14/2026
Date

Halperin Battaglia Benzija, LLP
40 Wall Street, 37th Floor
New York, NY 10005
Address

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. § 1320.4(a)(2) applies.

Debtor's Name Insys Therapeutics, Inc., Case No. 19-11292

Part 1: Summary of Post-confirmation Transfers

	Current Quarter	Total Since Effective Date
a. Total cash disbursements	$215,642	$29,834,238
b. Non-cash securities transferred	$0	$0
c. Other non-cash property transferred	$0	$0
d. Total transferred (a+b+c)	$215,642	$29,834,238

Part 2: Preconfirmation Professional Fees and Expenses

				Approved Current	Approved Cumulative	Paid Current Quarter	Paid Cumulative
a.	Professional fees & expenses (bankruptcy) incurred by or on behalf of the debtor *Aggregate Total*			$0	$0	$0	$10,199,965
	Itemized Breakdown by Firm						
		Firm Name	Role				
	i	ALTO Litigation	Special Counsel	$0	$0	$0	$2,838
	ii	Andersen Tax	Financial Professional	$0	$0	$0	$60,664
	iii	Carlton Fields	Other	$0	$0	$0	$435,811
	iv	Columbus	Other	$0	$0	$0	$3,900
	v	Dinsmore & Shohi	Special Counsel	$0	$0	$0	$4,538
	vi	DLA Piper	Special Counsel	$0	$0	$0	$3,942
	vii	Ernst & Young	Financial Professional	$0	$0	$0	$5,200
	viii	Epiq	Other	$0	$0	$0	$1,124,069
	ix	FTI Consulting	Financial Professional	$0	$0	$0	$3,891,025
	x	Gibbons	Special Counsel	$0	$0	$0	$8,525
	xi	Hampton Barghois Pierce	Special Counsel	$0	$0	$0	$3,483
	xii	Holland & Knight	Special Counsel	$0	$0	$0	$120,436
	xiii	Lazard Freres	Financial Professional	$0	$0	$0	$1,478,864
	xiv	Miller Friel	Special Counsel	$0	$0	$0	$69,684
	xv	Rakoczy Molion Mazzochi	Special Counsel	$0	$0	$0	$5,917
	xvi	Resolutions Inc.	Special Counsel	$0	$0	$0	$25,000
	xvii	Richards Layton & Finger	Special Counsel	$0	$0	$0	$1,018,507
	xviii	Rose Law Firm	Special Counsel	$0	$0	$0	$3,617
	xix	Shook Hardy & Bacon	Special Counsel	$0	$0	$0	$543
	xx	Spiro Harrison	Special Counsel	$0	$0	$0	$45,839
	xxi	Squire Patton Boggs	Special Counsel	$0	$0	$0	$354
	xxii	Weil Gotshal & Manges	Lead Counsel	$0	$0	$0	$1,759,519
	xxiii	Wilson Sonsini Goodrich & Ros	Special Counsel	$0	$0	$0	$127,690
	xxiv						
	xxv						
	xxvi						
	xxvii						
	xxviii						
	xxix						

Debtor's Name Insys Therapeutics, Inc., Case No. 19-11292

	xxx						
	xxxi						
	xxxii						
	xxxiii						
	xxxiv						
	xxxv						
	xxxvi						
	xxxvii						
	xxxviii						
	xxxix						
	xl						
	xli						
	xlii						
	xliii						
	xliv						
	xlv						
	xlvi						
	xlvii						
	xlviii						
	xlix						
	l						
	li						
	lii						
	liii						
	liv						
	lv						
	lvi						
	lvii						
	lviii						
	lix						
	lx						
	lxi						
	lxii						
	lxiii						
	lxiv						
	lxv						
	lxvi						
	lxvii						
	lxviii						
	lxix						
	lxx						
	lxxi						

Debtor's Name Insys Therapeutics, Inc., Case No. 19-11292

	lxxii						
	lxxiii						
	lxxiv						
	lxxv						
	lxxvi						
	lxxvii						
	lxxviii						
	lxxix						
	lxxx						
	lxxxi						
	lxxxii						
	lxxxiii						
	lxxxiv						
	lxxxv						
	lxxxvi						
	lxxxvii						
	lxxxvii						
	lxxxix						
	xc						
	xci						
	xcii						
	xciii						
	xciv						
	xcv						
	xcvi						
	xcvii						
	xcviii						
	xcix						
	c						
	ci						

				Approved Current	Approved Cumulative	Paid Current Quarter	Paid Cumulative
b.	Professional fees & expenses (nonbankruptcy) incurred by or on behalf of the debtor		*Aggregate Total*				
	Itemized Breakdown by Firm						
		Firm Name	Role				
	i						
	ii						
	iii						
	iv						
	v						
	vi						

Debtor's Name Insys Therapeutics, Inc., Case No. 19-11292

	vii						
	viii						
	ix						
	x						
	xi						
	xii						
	xiii						
	xiv						
	xv						
	xvi						
	xvii						
	xviii						
	xix						
	xx						
	xxi						
	xxii						
	xxiii						
	xxiv						
	xxv						
	xxvi						
	xxvii						
	xxviii						
	xxix						
	xxx						
	xxxi						
	xxxii						
	xxxiii						
	xxxiv						
	xxxv						
	xxxvi						
	xxxvii						
	xxxviii						
	xxxix						
	xl						
	xli						
	xlii						
	xliii						
	xliv						
	xlv						
	xlvi						
	xlvii						
	xlviii						

Debtor's Name Insys Therapeutics, Inc., Case No. 19-11292

	xlix						
	l						
	li						
	lii						
	liii						
	liv						
	lv						
	lvi						
	lvii						
	lviii						
	lix						
	lx						
	lxi						
	lxii						
	lxiii						
	lxiv						
	lxv						
	lxvi						
	lxvii						
	lxviii						
	lxix						
	lxx						
	lxxi						
	lxxii						
	lxxiii						
	lxxiv						
	lxxv						
	lxxvi						
	lxxvii						
	lxxviii						
	lxxix						
	lxxx						
	lxxxi						
	lxxxii						
	lxxxiii						
	lxxxiv						
	lxxxv						
	lxxxvi						
	lxxxvii						
	lxxxvii						
	lxxxix						
	xc						

Debtor's Name Insys Therapeutics, Inc., Case No. 19-11292

	xci						
	xcii						
	xciii						
	xciv						
	xcv						
	xcvi						
	xcvii						
	xcviii						
	xcix						
	c						
	ci						
c.	All professional fees and expenses (debtor & committees)					$0	$11,876,616

Part 3: Recoveries of the Holders of Claims and Interests under Confirmed Plan

	Total Anticipated Payments Under Plan	Paid Current Quarter	Paid Cumulative	Allowed Claims	% Paid of Allowed Claims
a. Administrative claims	$0	$0	$705,413	$705,413	100%
b. Secured claims	$0	$0	$0	$0	0%
c. Priority claims	$0	$0	$165,597	$165,597	100%
d. General unsecured claims	$0	$0	$0	$0	0%
e. Equity interests	$0	$0	$0		

Part 4: Questionnaire

a. Is this a final report? Yes ○ No ●

If yes, give date Final Decree was entered: ________

If no, give date when the application for Final Decree is anticipated: ________

b. Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C. § 1930? Yes ● No ○

Debtor's Name Insys Therapeutics, Inc., Case No. 19-11292

Privacy Act Statement

28 U.S.C. § 589b authorizes the collection of this information and provision of this information is mandatory. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6) and to otherwise evaluate whether a reorganized chapter 11 debtor is performing as anticipated under a confirmed plan. Disclosure of this information may be to a bankruptcy trustee when the information is needed to perform the trustee's duties, or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." *See* 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http://www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case, or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).

I declare under penalty of perjury that the foregoing Post-confirmation Report and its attachments, if any, are true and correct and that I have been authorized to sign this report.

/s/ William H. Henrich	William H. Henrich
Signature of Responsible Party	Printed Name of Responsible Party
Liquidating Trustee of the Insys Liquidation Trust	04/14/2026
Title	Date

Debtor's Name Insys Therapeutics, Inc., Case No. 19-11292

Page 1

Other Page 1

Page 2 Minus Tables

Bankruptcy Table 1-50

Debtor's Name Insys Therapeutics, Inc., Case No. 19-11292

Bankruptcy Table 51-100

Non-Bankruptcy Table 1-50

Non-Bankruptcy Table 51-100

Part 3, Part 4, Last Page